August 20, 2018 Environ, Ag./Food & Bev Licensing, IP, and Legal

Neogen’s one-hour Listeria Right Now™ receives AOAC approval

CONTACT: George Nagle, Neogen Corporation 517/372-9200 LANSING, Mich., Aug. 20, 2018 — Neogen’s revolutionary Listeria Right Now™ environmental pathogen detection system has officially achieved AOAC approval, license number #081802. The approval adds another level of assurance to the food safety community, as the product has now been validated by one of the industry’s leading third-party accreditation groups. “It’s extremely... Read more

August 15, 2018 Lab Top-10 Licensing, IP, and Legal Life Science Tools

Merck KGaA, Darmstadt, Germany, Awarded Australian CRISPR Nickase Patent for Foundational Genome-Editing Technology

Merck KGaA, Darmstadt, Germany, today announced that the Australian Patent Office has allowed the company’s patent application for the use of paired CRISPR nickases. 15 AUG 2018 | DARMSTADT, GERMANY Patent covers paired Cas9 nickase technology to reduce off-target effects, advance gene therapy and research Expands company’s foundational CRISPR cutting and integration IP necessary to correct genetic... Read more

August 13, 2018 Licensing, IP, and Legal

Successfully certified

2018-08-10 Certifications are essential in international business. “Worldwide, and especially in Asia, customers are more and more looking for companies with comprehensive certifications,” explains Elisabeth Hofstätter-Kollarich, head of Quality & Management Systems at Anton Paar. Our company has been ISO 9001 certified for a long time, which confirms our high standards for the quality of... Read more

July 31, 2018 Licensing, IP, and Legal

Fluidic Analytics Secures US Patent Paving the Way for the Development and Commercialization of Next-generation Protein Analysis Technology Platform

Cambridge, UK – (31 July 2018) Fluidic Analytics Ltd, has announced the issuance of US Patent 9,952,22 B2, entitled ‘Fluidic Separation and Detection’, from the United States Patent and Trademark Office. This paves the way for the development and commercialization of a next-generation protein analysis technology platform to be launched later this year. “The issuance... Read more

July 25, 2018 Clinical Research/Diagn. Licensing, IP, and Legal

Takara Bio granted manufacturing license from the Swedish Medical Product Agency for clinical-grade human embryonic stem cell line derivation and banking

MOUNTAIN VIEW, Calif., July 25, 2018 /PRNewswire/ — Takara Bio announced today that the Medical Products Agency (“MPA”), the Swedish national authority responsible for regulation and surveillance of the development, manufacturing and marketing of drug and other medical products, granted a manufacturing license for derivation and banking of human embryonic stem (hES) cells to be produced under GMP... Read more

July 22, 2018 Bio/Pharma/CRO Licensing, IP, and Legal Life Science Tools

Gyros Protein Technologies and Cygnus Technologies sign licensing and supply agreement

Uppsala, Sweden and Southport, N.C., July 10, 2018: Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and leading provider of peptide synthesizers and reagents, and Cygnus Technologies, the leading assay and services provider for the detection and characterization of impurities in biopharmaceuticals, today announced they have signed a licensing and supply agreement. Under the... Read more

July 18, 2018 Cell Analysis Tools Licensing, IP, and Legal Life Science Tools

Takara Bio strengthens its IP position on single cell RNA-seq

MOUNTAIN VIEW, Calif., July 18, 2018 /PRNewswire/ — Takara Bio USA, Inc., (TBUSA, formerly Clontech Laboratories, Inc.), a wholly owned subsidiary of Takara Bio Inc., is proud to announce that patent JP6336080B—covering the Smart-seq2 method, developed by Rickard Sandberg and exclusively licensed to TBUSA by the Ludwig Institute—has been awarded by the Japan Patent Office. Additional patents regarding the Smart-seq2 technology... Read more

July 16, 2018 Environ, Ag./Food & Bev Licensing, IP, and Legal Product Launch

GE Healthcare launches Omnipaque Oral Solution, a ready-to-drink iodinated contrast medium for computed tomography of the abdomen

Boston, MA, USA –July 16, 2018 – GE Healthcare is launching OmnipaqueTM (iohexol) Oral Solution in the United States, a new, ready-to-drink iodinated contrast medium that can be used to help physicians diagnose medical conditions by improving the diagnostic visualization of the abdominal gastrointestinal tract.  Omnipaque oral solution is indicated for oral use only in... Read more

July 2, 2018 Bio/Pharma/CRO Licensing, IP, and Legal PR/Corporate

Phase III IMpassion130 study showed Roche’s Tecentriq plus Abraxane significantly reduced the risk of disease worsening or death in people with metastatic triple negative breast cancer

Basel, 02 July 2018 Phase III IMpassion130 study showed Roche’s Tecentriq plus Abraxane significantly reduced the risk of disease worsening or death in people with metastatic triple negative breast cancer First Phase III immunotherapy study to demonstrate a statistically significant improvement in progression-free survival (PFS) in the intention-to-treat (ITT) and PD-L1 positive first-line metastatic triple... Read more